ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous HLA-A*02:01-restricted Mutant NPM1-directed TCR-expressing T-lymphocytes BSB-2002

Also written as “SOC+ BSB-2002” and “SOC+BSB-2002”.

Its studies are mostly in Leukemia, Myeloid, Acute, led by BlueSphere Bio.

Furthest: phase 1, since Apr 21, 20261 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BlueSphere Bio10 open or runningphase 1since Apr 21, 2026Apr 21, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 21, 2026First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT07566585 · United States

TargetBeta

NPM1 →read by rule
“A preparation of autologous T-lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A*02:01-restricted mutated nucleophosmin (NPM1; nucleolar phosphoprotein B23), ”NCIt, by rule

Other programs on NPM1

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07566585Leukemia, Myeloid, Acute · United States1WithdrawnSep 8, 20260

How it is read

Names in the registry

  • “SOC+ BSB-2002”, 1 entry
  • “SOC+BSB-2002”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.